Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: Results from PHOENIX 1

British Journal of Dermatology

Volumn 170, Issue 2, 2014, Pages 398-407

  Rich, P ^a   Bourcier, M ^b   Sofen, H ^c   Fakharzadeh, S ^d   Wasfi, Y ^e   Wang, Y ^e   Kerkmann, U ^f   Ghislain, P D ^g   Poulin, Y ^h  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Dermatology Clinic   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Janssen Biotech Inc   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f Janssen Biologics   (Netherlands)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h Centre Dermatologique du Quebec Metropolitain   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES, MONOCLONAL, HUMANIZED; CROSS-OVER STUDIES; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAIL DISEASES; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84894274228     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12632     Document Type: Article

References (49)

1. Rich P, Griffiths CEM, Reich K, et al,. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224-31.
2. Reich K,. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 1): 15-21.
3. Williamson L, Dalbeth N, Dockerty JL, et al,. Extended report: nail disease in psoriatic arthritis clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004; 43: 790-4.
4. Lavaroni G, Kokelj F, Pauluzzi P, Trevisan G,. The nails in psoriatic arthritis. Acta Derm Venereol Suppl (Stockh) 1994; 186: 113.
5. Wilson FC, Icen M, Crowson CS, et al,. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009; 61: 233-9.
6. Elkayam O, Ophir J, Yaron M, Caspi D,. Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 2000; 19: 301-5.
7. McGonagle D,. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 1): 9-13.
8. Klaassen KM, van de Kerkhof PC, Pasch MC,. Nail psoriasis: a questionnaire-based survey. Br J Dermatol 2013; 169: 314-19.
9. de Jong EM, Seegers BA, Gulinck MK, et al,. Psoriasis of the nails associated with disability in a larger number of patients: results of a recent interview with 1,728 patients. Dermatology 1996; 193: 300-3.
10. Tan ES, Chong WS, Tey HL,. Nail psoriasis: a review. Am J Clin Dermatol 2012; 13: 375-88.
11. Lawry M,. Biological therapy and nail psoriasis. Dermatol Ther 2007; 20: 60-7.
12. Jiaravuthisan MM, Sasseville D, Vender RB, et al,. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1-27.
13. De Berker D,. Management of psoriatic nail disease. Semin Cutan Med Surg 2009; 28: 39-43.
14. Sanchez-Regana M, Sola-Ortigosa J, Alsina-Gilbert M, et al,. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol 2011; 25: 579-86.
15. de Vries ACQ, Bogaards NA, Hooft L, et al,. Interventions for nail psoriasis (review). Cochrane Database Syst Rev 2013; 1: CD007633.
16. Oram Y, Akkaya AD,. Treatment of nail psoriasis: common concepts and new trends. Dermatol Res Pract 2013; 2013: 180496.
17. Farber EM, Nall L,. Nail psoriasis. Cutis 1992; 50: 174-8.
18. Raval K, Lofland JH, Waters HC, Piech CT,. Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol 2011; 10: 189-96.
19. Noiles K, Vender R,. Nail psoriasis and biologics. J Cutan Med Surg 2009; 13: 1-5.
20. Irla N, Yawalkar N,. Marked improvements in nail psoriasis during treatment with adalimumab. Dermatology 2009; 219: 353-6.
21. Rigopoulos D, Gregoriou S, Lazaridou E, et al,. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010; 24: 530-4.
22. Rallis E, Stavropoulou E, Rigopoulos D, Verros C,. Rapid response of nail psoriasis to etanercept. J Rheumatol 2008; 35: 544-5.
23. Luger TA, Barker J, Lambert J, et al,. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 896-904.
24. Körver JEM, Langewouters AMG, Van De Kerkhof PCM, Pasch MC,. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 1252-5.
25. Jemec GBE, Ibler KS,. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors. J Drugs Dermatol 2012; 11: 939-42.
26. Ortonne JP, Paul C, Berardesca E, et al,. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol 2013; 168: 1080-7.
27. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
28. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
29. Griffiths CEM, Strober BE, van de Kerkhof P, et al,. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
30. Kimball AB, Gordon KB, Fakharzadeh S, et al,. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012; 166: 861-72.
31. McInnes IB, Kavanaugh A, Gottlieb AB, et al,. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT1 trial. Lancet 2013; 382: 780-9.
32. Reich K, Papp KA, Griffiths CE, et al,. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012; 11: 300-12.
33. Gordon KB, Papp KA, Langley RG, et al,. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 2012; 66: 742-51.
34. Lebwohl M, Leonardi C, Griffiths CEM, et al,. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2012; 66: 731-41.
35. Reich K, Langley RG, Lebwohl M, et al,. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164: 862-72.
36. Papp KA, Griffiths CEM, Gordon K, et al,. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-54.
37. Patsatsi A, Kyriakou A, Sotiriadis D,. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J Dermatolog Treat 2013; 24: 96-100.
38. Vitiello M, Tosti A, Abuchar A, et al,. Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients. Int J Dermatol 2013; 52: 358-62.
39. Rigopoulos D, Gregoriou S, Makris M, Ioannides D,. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology 2011; 223: 325-9.
40. Rich P, Scher R,. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-12.
41. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
42. Reich K, Ortonne J-P, Kerkmann U, et al,. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS trial. Dermatology 2010; 221: 172-8.
43. Kyriakou A, Patsatsi A, Sotiriadis D,. Anti-TNF agents and nail psoriasis: a single centre, retrospective, comparative study. J Dermatolog Treat 2013; 24: 162-8.
44. Zachariae R, Zachariae H, Blomqvist K, et al,. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002; 146: 1006-16.
45. Augustin M, Reich K, Blome C, et al,. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163: 580-5.
46. Langley RG, Saurat JH, Reich K,. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol 2012; 26: 373-81.
47. Aktan S, Ilknur T, Akin C, Ozkan S,. Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol 2007; 32: 141-4.
48. Augustin M, Ogilvie A,. Methods of outcomes measurement in nail psoriasis. Dermatology 2010; 221 (Suppl. 1): 23-8.
49. Cassell SE, Bieber JD, Rich P, et al,. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007; 34: 123-9.